HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for HYPOPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HYPOPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo offers hope for hard-to-treat head and neck cancer
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink or control advanced head and neck cancer that has grown after initial therapy. About 40 adults whose cancer has spread or returned will receive the combination. The goal is to see how ma…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New program aims to speed up radiation for head and neck cancer patients
Disease control Recruiting nowThis trial tests a program called ENDURE that helps head and neck cancer patients start radiation therapy within 6 weeks after surgery. The program provides education, social support, and better coordination among doctors. Researchers will compare it to usual care in 532 adults w…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Smarter radiation for head & neck cancer: Biopsy-Guided treatment may spare patients from dry mouth
Disease control Recruiting nowThis phase 3 trial tests whether using a sentinel lymph node biopsy to guide radiation can safely reduce the amount of neck radiation in people with certain head and neck cancers. The goal is to lower long-term side effects like severe dry mouth while still controlling the cancer…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC